Table 1 Baseline demographics
Number of patients | 786 |
Age (mean ± SD years; range) | 67 ± 12 (27-92) |
Male/female (%) | 73/27 |
Underlying liver disease (%) | Â |
   HBsAg-positive | 393 (50) |
   HBsAg-negative |  |
Anti-HCV-positive | 265 (34) |
Anti-HCV-negative | 128 (16) |
Tumoral characteristics (%) | Â |
   Single lesion | 500 (64) |
   Multi-nodular lesions | 286 (36) |
   Maximal tumor diameter |  |
≤ 5 cm | 566 (72) |
>5 cm | 220 (28) |
Ascites (%) | Â |
   Yes | 101 (13) |
   No | 685 (87) |
Serum AFP level (ng/mL) (%) | Â |
   Median (range) | 29 (2-10,032,600) |
   <20 | 344 (44) |
   20 - 400 | 288 (37) |
   >400 | 154 (19) |
Performance status (%) | Â |
   ECOG scale 0 | 590 (75) |
   ECOG scale 1-3 | 196 (25) |
Serum biochemistries (mean ± SD) |  |
   Albumin (g/dL) | 3.7 ± 0.6 |
   Bilirubin (mg/dL) | 1.1 ± 1.0 |
   Creatinine (mg/dL) | 1.3 ± 3.2 |
   Prothrombin time INR | 1.1 ± 0.3 |
   ALT (IU/L) | 69 ± 68 |
   AST (IU/L) | 52 ± 44 |
Child-Pugh-Turcotte class (%) | Â |
   A | 639 (81) |
   B | 147 (19) |
MELD score (mean ± SD; range) (%) | 9.3 ± 3.1 (6.4-23.9) |
   <8 | 336 (43) |
   8-11 | 215 (27) |
   >11 | 235 (30) |
Vascular invasion (%) | Â |
   No | 699 (9) |
   Yes | 87 (91) |
CLIP staging (%) | Â |
   Score 0 | 266 (34) |
   Score 1 | 276 (35) |
   Score 2 | 141 (18) |
   Score 3 | 66 (8) |
   Score 4 or 5 | 37 (5) |
Total tumor volume (cm3) (%) | Â |
   Mean ± SD (range) | 177 ± 436 (0.1-3,591) |
   Median | 21 |
   <10 | 297 (38) |
   10-50 | 226 (29) |
   50-200 | 121 (15) |
   200-500 | 57 (7) |
   >500 | 85 (11) |
Treatment (%) | Â |
   PAI or PEI | 79 (10) |
   RFA | 221 (28) |
   TACE | 471 (60) |
   More than one methods | 15 (2) |